| Literature DB >> 32521776 |
Bach Xuan Tran1,2, Giang Hai Ha3,4, Long Hoang Nguyen5, Giang Thu Vu6, Men Thi Hoang3,4, Huong Thi Le1, Carl A Latkin2, Cyrus S H Ho7, Roger C M Ho8,9.
Abstract
Novel coronavirus disease 19 (COVID-19) is a global threat to millions of lives. Enormous efforts in knowledge production have been made in the last few months, requiring a comprehensive analysis to examine the research gaps and to help guide an agenda for further studies. This study aims to explore the current research foci and their country variations regarding levels of income and COVID-19 transmission features. This textual analysis of 5780 publications extracted from the Web of Science, Medline, and Scopus databases was performed to explore the current research foci and propose further research agenda. The Latent Dirichlet allocation was used for topic modeling. Regression analysis was conducted to examine country variations in the research foci. Results indicate that publications are mainly contributed by the United States, China, and European countries. Guidelines for emergency care and surgical, viral pathogenesis, and global responses in the COVID-19 pandemic are the most common topics. There is variation in the research approaches to mitigate COVID-19 problems in countries with different income and transmission levels. Findings highlighted the need for global research collaborations among high- and low/middle-income countries in the different stages of pandemic prevention and control.Entities:
Keywords: COVID-19; content analysis; scientometrics; text mining
Mesh:
Year: 2020 PMID: 32521776 PMCID: PMC7312200 DOI: 10.3390/ijerph17114095
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Search query (Web of Science).
| No | Search Query | Result |
|---|---|---|
| 1 | TS = (“COVID-19”) | 998 |
| 2 | TS = (“2019 novel coronavirus”) | 151 |
| 3 | TS = (“2019-nCoV”) | 255 |
| 4 | TS = (“severe acute respiratory syndrome coronavirus 2”) | 84 |
| 5 | TS = (“SARS-CoV-2”) | 286 |
| 6 | #5 OR #4 OR #3 OR #2 OR #1 | 1304 |
| 7 | #5 OR #4 OR #3 OR #2 OR #1 Refined by: [excluding] PUBLICATION YEARS: (2011 OR 2003) | 1302 |
| 8 | #5 OR #4 OR #3 OR #2 OR #1 Refined by: [excluding] PUBLICATION YEARS: (2011 OR 2003) AND [excluding] DOCUMENT TYPES: (CORRECTION OR DATA PAPER OR REPRINT ) | 1281 |
| 9 | #5 OR #4 OR #3 OR #2 OR #1 Refined by: [excluding] PUBLICATION YEARS: (2011 OR 2003) AND [excluding] DOCUMENT TYPES: (CORRECTION OR DATA PAPER OR REPRINT) AND [excluding] AUTHORS: ( ANONYMOUS) | 1247 |
| 10 | #5 OR #4 OR #3 OR #2 OR #1 Refined by: [excluding] PUBLICATION YEARS: ( 2011 OR 2003 ) AND [excluding] DOCUMENT TYPES: (CORRECTION OR DATA PAPER OR REPRINT ) AND [excluding] AUTHORS: ( ANONYMOUS ) AND [excluding] LANGUAGES: ( GERMAN OR HUNGARIAN OR FRENCH OR PORTUGUESE OR ITALIAN OR SPANISH OR TURKISH OR CZECH OR NORWEGIAN ) | 1207 |
Search query (MEDLINE/PubMed).
| No | Search Query | Result |
|---|---|---|
| 1 | Search ((((“COVID-19”[Title/Abstract]) OR “2019 novel coronavirus”[Title/Abstract]) OR “2019-nCoV”[Title/Abstract]) OR “severe acute respiratory syndrome coronavirus 2”[Title/Abstract]) OR “SARS-CoV-2”[Title/Abstract] | 5779 |
Search query (Scopus).
| No | Search Query | Result |
|---|---|---|
| 1 | ( TITLE-ABS-KEY ( “COVID-19” ) ) OR ( TITLE-ABS-KEY ( “2019 novel coronavirus” ) ) OR ( TITLE-ABS-KEY ( “2019-nCoV” ) ) OR ( TITLE-ABS-KEY ( “severe acute respiratory syndrome coronavirus 2” ) ) OR ( TITLE-ABS-KEY ( “SARS-CoV-2” ) ) | 3348 |
| 2 | ( TITLE-ABS-KEY ( “COVID-19” ) ) OR ( TITLE-ABS-KEY ( “2019 novel coronavirus” ) ) OR ( TITLE-ABS-KEY ( “2019-nCoV” ) ) OR ( TITLE-ABS-KEY ( “severe acute respiratory syndrome coronavirus 2” ) ) OR ( TITLE-ABS-KEY ( “SARS-CoV-2” ) ) AND ( EXCLUDE ( PUBYEAR , 2011 ) OR EXCLUDE ( PUBYEAR , 2006 ) OR EXCLUDE ( PUBYEAR , 2004 ) OR EXCLUDE ( PUBYEAR , 2003 ) ) | 3309 |
| 3 | ( TITLE-ABS-KEY ( “COVID-19” ) ) OR ( TITLE-ABS-KEY ( “2019 novel coronavirus” ) ) OR ( TITLE-ABS-KEY ( “2019-nCoV” ) ) OR ( TITLE-ABS-KEY ( “severe acute respiratory syndrome coronavirus 2” ) ) OR ( TITLE-ABS-KEY ( “SARS-CoV-2” ) ) AND ( EXCLUDE ( PUBYEAR , 2011 ) OR EXCLUDE ( PUBYEAR , 2006 ) OR EXCLUDE ( PUBYEAR , 2004 ) OR EXCLUDE ( PUBYEAR , 2003 ) ) AND ( EXCLUDE ( DOCTYPE , “er” ) OR EXCLUDE ( DOCTYPE , “cp” ) OR EXCLUDE ( DOCTYPE , “dp” ) ) | 3309 |
| 4 | ( TITLE-ABS-KEY ( “COVID-19” ) ) OR ( TITLE-ABS-KEY ( “2019 novel coronavirus” ) ) OR ( TITLE-ABS-KEY ( “2019-nCoV” ) ) OR ( TITLE-ABS-KEY ( “severe acute respiratory syndrome coronavirus 2” ) ) OR ( TITLE-ABS-KEY ( “SARS-CoV-2” ) ) AND ( EXCLUDE ( PUBYEAR , 2011 ) OR EXCLUDE ( PUBYEAR , 2006 ) OR EXCLUDE ( PUBYEAR , 2004 ) OR EXCLUDE ( PUBYEAR , 2003 ) ) AND ( EXCLUDE ( DOCTYPE , “er” ) OR EXCLUDE ( DOCTYPE , “cp” ) OR EXCLUDE ( DOCTYPE , “dp” ) ) AND ( EXCLUDE ( PREFNAMEAUID , “Undefined#Undefined” ) ) | 3295 |
| 5 | ( TITLE-ABS-KEY ( “COVID-19” ) ) OR ( TITLE-ABS-KEY ( “2019 novel coronavirus” ) ) OR ( TITLE-ABS-KEY ( “2019-nCoV” ) ) OR ( TITLE-ABS-KEY ( “severe acute respiratory syndrome coronavirus 2” ) ) OR ( TITLE-ABS-KEY ( “SARS-CoV-2” ) ) AND ( EXCLUDE ( PUBYEAR , 2011 ) OR EXCLUDE ( PUBYEAR , 2006 ) OR EXCLUDE ( PUBYEAR , 2004 ) OR EXCLUDE ( PUBYEAR , 2003 ) ) AND ( EXCLUDE ( DOCTYPE , “er” ) OR EXCLUDE ( DOCTYPE , “cp” ) OR EXCLUDE ( DOCTYPE , “dp” ) ) AND ( EXCLUDE ( PREFNAMEAUID , “Undefined#Undefined” ) ) AND ( EXCLUDE ( SUBJAREA , “Undefined” ) ) AND ( EXCLUDE ( LANGUAGE , “Chinese” ) OR EXCLUDE ( LANGUAGE , “German” ) OR EXCLUDE ( LANGUAGE , “Spanish” ) OR EXCLUDE ( LANGUAGE , “French” ) OR EXCLUDE ( LANGUAGE , “Norwegian” ) OR EXCLUDE ( LANGUAGE , “Portuguese” ) OR EXCLUDE ( LANGUAGE , “Italian” ) OR EXCLUDE ( LANGUAGE , “Dutch” ) OR EXCLUDE ( LANGUAGE , “Icelandic” ) OR EXCLUDE ( LANGUAGE , “Korean” ) OR EXCLUDE ( LANGUAGE , “Swedish” ) OR EXCLUDE ( LANGUAGE , “Turkish” ) ) | 3032 |
Figure 1Selection process.
Figure 2Number of publications per country
Top ten most cited papers.
| No. | Title | Journal (IF) | Number of Citations | Main Findings |
|---|---|---|---|---|
| 01 | Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study | The Lancet (IF = 59·1) | 319 |
SARS-CoV-2 infection was of clustering onset, and more likely to affect older males with comorbidities. Patients had clinical manifestations of fever, cough, shortness of breath, muscle ache, confusion, headache, sore throat, rhinorrhea, chest pain, diarrhea, and nausea and vomiting. Imaging examination revealed bilateral pneumonia, multiple mottling, and ground-glass opacity. |
| 02 | A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster | The Lancet (IF = 59·1) | 245 |
Results confirmed that SARS-CoV-2 was transmitted through person-to-person contact. Older patients (aged >60 years) had more systemic symptoms, extensive radiological ground-glass lung changes, lymphopenia, thrombocytopenia, and increased C-reactive protein and lactate dehydrogenase levels. Phylogenetic analysis of showed that this is a novel coronavirus, which is closest to the bat severe acute respiratory syndrome (SARS)-related coronaviruses found in Chinese horseshoe bats. |
| 03 | Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records | The Lancet (IF = 59·1) | 75 |
Clinical characteristics of COVID-19 pneumonia in pregnant women were similar to those reported for non-pregnant adult patients. Fevers, cough, myalgia, sore throat, and malaise were also observed. No neonatal asphyxia was observed in newborn babies. |
| 04 | Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR | Eurosurveillance (IF = 7·4) | 74 |
The laboratory diagnostic workflow for detection of SARS-CoV-2 was described and validated. |
| 05 | Emerging coronaviruses: Genome structure, replication, and pathogenesis | Journal of Medical Virology (IF = 2·0) | 51 |
Available understanding on genome structure and replication, and functions proteins in coronaviral replication of coronaviruses (CoVs) were reviewed. SARS-CoV-2 has a typical genome structure of CoV and belongs to the cluster of betacoronaviruses, including Bat-SARS-like (SL)-ZC45, Bat-SL ZXC21, SARS-CoV, and MERS-CoV. |
| 06 | CT imaging features of 2019 novel coronavirus (2019-NCoV) | Radiology (IF = 7·6) | 51 |
Typical CT findings included bilateral pulmonary parenchymal ground-glass and consolidative pulmonary opacities, sometimes with a rounded morphology and a peripheral lung distribution. Lung cavitation, discrete pulmonary nodules, pleural effusions, and lymphadenopathy were absent. |
| 07 | Presumed Asymptomatic Carrier Transmission of COVID-19 | JAMA - Journal of the American Medical Association (IF = 51·3) | 49 |
All symptomatic patients had multifocal ground-glass opacities on chest CT, and 1 also had subsegmental areas of consolidation and fibrosis. All the symptomatic patients had increased C-reactive protein levels and reduced lymphocyte counts. The coronavirus may have been transmitted by the asymptomatic carrier. |
| 08 | Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies | BioScience Trends (IF = 1·7) | 48 |
Chloroquine phosphate is superior to the control treatment in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting a virus-negative conversion, and shortening the disease course according to the news briefing. Severe adverse reactions to chloroquine phosphate were not noted in the patients in trial. |
| 09 | Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan | Emerging Microbes and Infections (IF = 6·2) | 46 |
Genome of SARS-CoV-2 has 89% nucleotide identity with bat SARS-like-CoVZXC21 and 82% with that of human SARS-CoV. Phylogenetic trees of their orf1a/b, Spike, Envelope, Membrane and Nucleoprotein clustered closely with those of the bat, civet, and human SARS coronaviruses. |
| 10 | Incubation period of 2019 novel coronavirus (2019- nCoV) infections among travelers from Wuhan, China, 20–28 January 2020 | Eurosurveillance (IF = 7·4) | 30 |
The mean incubation period was estimated to be 6.4 days (95% credible interval: 5.6–7.7), ranging from 2.1 to 11.1 days (2.5th to 97.5th percentile). |
Figure 3Co-occurrence analysis of keywords.
Figure 4Co-occurrence analysis of the most frequent terms.
Figure 5Dendrogram of research areas in WOS database.
Fifteen topics about COVID-19 according to topic modeling.
| Topic | Content | Top Ten Most Frequent Terms |
| % |
|---|---|---|---|---|
| Topic 1 | Epidemiological reports on COVID-19 outbreaks in different countries. | Covid-19; cases; transmission; first; disease; coronavirus; march; countries; confirmed; and health. | 295 | 5.1 |
| Topic 2 | Global and international health security and responses in COVID-19 pandemic crisis. | Health; covid-19; pandemic; public; global; response; community; world; emergency; and outbreak. | 571 | 9.9 |
| Topic 3 | SARS-CoV-2 virus structure and molecular analysis. | Sars-cov-2; 2019-ncov; human; coronavirus; sars-cov; protein; virus; viral; spike; and receptor. | 231 | 4.0 |
| Topic 4 | Distinguishes between old and novel coronavirus: origin, pathology, and pathogenesis. | Coronavirus; respiratory; novel; china; disease; sars-cov-2; severe; syndrome; acute; and outbreak. | 611 | 10.6 |
| Topic 5 | Radiographic detection of COVID-19. | Covid-19; patients; symptoms; pneumonia; chest; clinical; disease; children; findings; and imaging. | 310 | 5.4 |
| Topic 6 | Psychological disorders in COVID-19 epidemic: epidemiological characteristics and interventions. | Covid-19; health; mental; during; outbreak; study; social; psychological; anxiety; and media. | 256 | 4.4 |
| Topic 7 | Clinical and laboratory examinations in hospitalized patients with COVID-19. | Patients; covid-19; clinical; severe; study; group; cases; disease; results; Wuhan | 232 | 4.0 |
| Topic 8 | Comorbidities in patients with COVID-19. | covid-19; patients; disease; respiratory; severe; acute; infection; syndrome; article; and coronavirus. | 474 | 8.2 |
| Topic 9 | Impacts of COVID-19 on pregnancy outcomes. | Covid-19; review; studies; evidence; women; pregnant; clinical; research; literature; and results. | 156 | 2.7 |
| Topic 10 | Diagnostic values of SARS-CoV-2 tests and improvement strategies. | Sars-cov-2; positive; covid-19; viral; testing; detection; rt-pcr; samples; results; and negative. | 234 | 4.1 |
| Topic 11 | Guidelines for emergency care and surgical management during COVID-19 pandemic. | Covid-19; pandemic; patients; during; management; cancer; hospital; recommendations; clinical; and surgery. | 669 | 11.6 |
| Topic 12 | Global logistics concerns in COVID-19 prevention, treatment and care. | Covid-19; protective; transmission; healthcare; workers; equipment; personal; during; infection; and staff. | 242 | 4.2 |
| Topic 13 | Medical education in COVID-19 pandemic. | Covid-19; pandemic; medical; education; medicine; during; response; lessons; students; and nursing. | 561 | 9.7 |
| Topic 14 | COVID-19 epidemiological modelling and forecasting. | Covid-19; cases; china; epidemic; number; outbreak; model; Wuhan; measures; and confirmed. | 292 | 5.1 |
| Topic 15 | Treatment interventions against COVID-19. | Covid-19; treatment; drugs; clinical; therapeutic; against; antiviral; sars-cov-2; therapy; and effective. | 311 | 5.4 |
Regression models to identify the research trend among countries with different income level and epidemic characteristics.
| Topic | World Bank Income Classification 1 | WHO COVID-19 Transmission Classification 2 | ||||
|---|---|---|---|---|---|---|
| Low-Middle Income Countries | High-Middle | High Income | Sporadic Cases | Clusters of Cases | Community | |
| Coef. (95%CI) | Coef. (95%CI) | Coef. (95%CI) | Coef. (95%CI) | Coef. (95%CI) | Coef. (95%CI) | |
| Topic 1 | 4.7 (−4.7; 14.0) | 6.8 (−6.9; 20.4) | 14 (−6.4; 34.5) | −1.1 (−9.1; 6.9) | 3 (−3.8; 9.7) | 6.7 (−0.7; 14.1) |
| Topic 2 | 3.4 (−12.2; 18.9) | −7.1 (−29.8; 15.5) | −10.4 (−44.4; 23.6) | −5.3 (−18.6; 7.9) | −3 (−14.2; 8.3) | 2.2 (−10.1; 14.4) |
| Topic 3 | 1 (−2.7; 4.7) | 1.9 (−3.5; 7.3) | 1.3 (−6.8; 9.4) | −0.9 (−4.1; 2.2) | 1 (−1.7; 3.6) | 0.2 (−2.7; 3.2) |
| Topic 4 | 2 (−9.0; 13.0) | 3 (−13.1; 19.0) | 8.2 (−15.8; 32.3) | 1.2 (−8.2; 10.5) | 6 (−2.0; 14.0) | 5.2 (−3.4; 13.9) |
| Topic 5 | −1 (−2.7; 0.8) | −0.8 (−3.4; 1.7) | −2.6 (−6.4; 1.2) | −1.5 (−2.9; 0.0) | −1 (−2.3; 0.3) | −1.4 (−2.8; 0.0) |
| Topic 6 | −6.4 (−12.4; −0.4) * | −16.9 (−25.6; −8.1) * | −23.5 (−36.6; −10.4) * | 4.6 (−0.5; 9.7) | 1.3 (−3.0; 5.7) | 2 (−2.7; 6.7) |
| Topic 7 | −0.1 (−1.6; 1.3) | 0.3 (−1.8; 2.4) | 0.7 (−2.5; 3.8) | 0 (−1.2; 1.2) | 0.4 (−0.7; 1.4) | 0.7 (−0.4; 1.9) |
| Topic 8 | 2.8 (−3.4; 9.1) | −0.2 (−9.3; 8.9) | 3.4 (−10.3; 17.1) | −5.8 (−11.2; −0.5) * | −4.1 (−8.7; 0.4) | 1.7 (−3.3; 6.6) |
| Topic 9 | 2.2 (−2.9; 7.2) | 0.9 (−6.5; 8.3) | 0.9 (−10.1; 12.0) | −0.3 (−4.6; 4.0) | 2.1 (−1.6; 5.8) | 2.5 (−1.5; 6.4) |
| Topic 10 | −1.5 (−2.9; −0.1) * | −1.9 (−3.9; 0.1) | −2.7 (−5.6; 0.3) | −0.3 (−1.5; 0.8) | 0.4 (−0.6; 1.4) | 0 (−1.1; 1.0) |
| Topic 11 | −10.2 (−20.9; 0.5) | −13.7 (−29.3; 1.8) | −19.6 (−42.9; 3.8) | −2.2 (−11.3; 6.9) | −0.2 (−7.9; 7.6) | 1.7 (−6.8; 10.1) |
| Topic 12 | −1.5 (−4.3; 1.4) | −3.2 (−7.3; 1.0) | −3.1 (−9.2; 3.1) | −0.6 (−3.0; 1.8) | −1.1 (−3.1; 1.0) | −0.8 (−3.0; 1.4) |
| Topic 13 | −4.9 (−13.2; 3.3) | −7.6 (−19.6; 4.4) | −4.4 (−22.4; 13.7) | 0.8 (−6.2; 7.8) | 2.9 (−3.1; 8.9) | 2.1 (−4.4; 8.6) |
| Topic 14 | 1.7 (−7.4; 10.8) | −2.5 (−15.7; 10.8) | −3 (−22.8; 16.9) | −1 (−8.8; 6.7) | −2.9 (−9.5; 3.7) | −1 (−8.2; 6.1) |
| Topic 15 | 16.6 (6.5; 26.7) * | 19.9 (5.2; 34.6) * | 34.8 (12.8; 56.8) * | −20.8 (−29.3; −12.2) * | −18.9 (−26.2; −11.6) * | −17 (−24.9; −9) * |
* p < 0.05; 1 Compared to Low-income countries. The model was adjusted to natural logarithm of GDP per capita, number of cases, number of deaths, and WHO COVID-19 transmission classification; 2 Compared to Pending classification. The model was adjusted to natural logarithm of GDP per capita, number of cases, number of deaths, and World Bank Income Classification.